Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
Clinical trial NCT03094611 · TERMINATED
Trial details
- NCT number
- NCT03094611
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-30
- Primary completion
- 2020-03-11
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.